Global Guillain-Bare Syndrome Market Size, Share, and COVID-19 Impact Analysis, By Type (Acute Motor Axonal Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Acute Inflammatory Demyelinating Polyneuropathy, and Miller Fisher Syndrome), By Treatment (Plasma Exchange, Intravenous Immunoglobulin (IVIG), and Others), By Route of Administration (Parenteral and Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Guillain-Barre Syndrome Market Insights Forecasts to 2033

• The Global Guillain-Barre Syndrome Market Size was Estimated at USD 687.72 Million in 2023
• The Market Size is Expected to Grow at a CAGR of around 5.99% from 2023 to 2033
• The Worldwide Guillain-Barre Syndrome Market Size is Expected to reach USD 1230.51 Million by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Guillain-Barre Syndrome Market Size is predicted to Exceed USD 1230.51 Million by 2033, Growing at a CAGR of 5.99% from 2023 to 2033. The global Guillain-Barre syndrome market is driven by the rise in respiratory and gastrointestinal infections, the geriatric population's increased sensitivity to infectious diseases due to low immunity, and rising consumer awareness of early treatment's importance in reducing symptoms and improving outcomes.

Market Overview

The Guillain-Barre Syndrome (GBS) market emphasizes the diagnosing, treating, and management of a rare autoimmune disorder named Guillain-Barre Syndrome (GBS) by using therapeutics such as intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis). Guillain-Barré syndrome is a rare autoimmune condition where the immune system attacks peripheral nerves, causing numbness, tingling, and muscle weakness. It can progress to paralysis, but with treatment, most people fully recover. The condition can be sudden and unexpected and require immediate hospitalization. Campylobacter jejuni (C. jejuni) is the most common pathogen responsible for the initial infection leading to GBS, which is primarily spread through diet, particularly through ingestion of raw or undercooked poultry meat, fish, unpasteurized milk, or contaminated water.

The market for GBS is expected to grow due to rising incidence in infectious disease-prone regions, advancements in diagnostic techniques, and R&D efforts. The increasing prevalence of Guillain-Barre syndrome (GBS) cases is driving demand for diagnostic tools, treatments, and supportive care services. Healthcare providers are seeking advanced techniques and immunomodulatory therapies, driving market growth, and encouraging investments in research to improve patient outcomes and quality of life.

Several government initiatives providing financial support to the population for managing GBS escalate the need for treatment, resulting in market growth. For instance, the Pune Municipal Corporation has taken proactive measures to address the surge in Guillain-Barré Syndrome cases, with 74 reported in the past three weeks and 14 requiring ventilator support. Under the leadership of the Municipal Commissioner and in coordination with the Union Minister, the Pune Municipal Corporation has delivered timely medical and financial assistance to affected citizens. The Urban Poor Scheme offers up to rupees 2 lakh in financial aid to eligible patients receiving treatment at private hospitals. PMC provides free immunoglobulin injections to both government and private hospitals, while municipal health officials manage medical billing. PMC has intensified surveillance and public health initiatives to curb the spread of disease and promote community well-being.

The Union Ministry of Health and Family Welfare has sent a multi-disciplinary team to Pune, Maharashtra, to assist state health authorities in implementing public health interventions and management due to an increase in suspected and confirmed cases of Guillain-Barre Syndrome. The team, including experts from the National Center for Disease Control, NIMHANS Bengaluru, Regional Office of Health & Family Welfare, and National Institute for Virology, Pune, work closely with State Health Departments to assess the situation and recommend necessary public health interventions. Therefore, monitoring the patient's health and diagnosing the diseases with the provision of treatment accelerates the demand of therapies and medications for the management of the Guillain-Barre syndrome, which propels the market growth.

The rising cases of GBS accelerate the need for treatment and promote the awareness of GBS worldwide. For example, Guillain-Barre Syndrome (GBS) is a global health issue with a median incidence of 1.3 cases per 100,000 population, with males being more affected. Peaks occur in young adults and the elderly. There's no clear seasonal association in Western countries, possibly due to the opposite seasonality of respiratory and enteric infections. Campylobacter jejuni infection is the most common cause, associated with severe disease and prolonged disability.

Increased awareness of neurological problems, improvements in healthcare, and research into immunotherapy and plasmapheresis procedures all contribute to the growth of the Guillain-Barre syndrome market.

Report Coverage

This research report categorizes the global Guillain-Barre syndrome market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global Guillain-Barre syndrome market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global Guillain-Barre syndrome market.

Driving factors

Increasing prevalence of the Guillain-Barre syndrome:

Guillain-Barre Syndrome (GBS) is a global health issue caused by a combination of factors. GBS is an acute immune-mediated polyneuropathy that often occurs after infections or other immune stimulations. The increasing prevalence of infectious diseases, such as respiratory and gastrointestinal infections, the post-infectious nature of GBS underscores the need for controlling infectious diseases. There are concerns about a potential link between certain vaccinations and GBS, but these are rare. Genetic predisposition and environmental factors may also contribute to GBS susceptibility, and ongoing research is exploring these connections to better understand the syndrome's underlying mechanisms.

Rising proportion of the geriatric population:

The immune system deliberately targets the peripheral nerve system in GBS, an autoimmune disease. An autoimmune reaction may result from respiratory and gastrointestinal illnesses, which are more common in elderly people. In elderly people, some vaccinations, such as the influenza vaccine, have been linked to an elevated risk of GBS. As elderly individuals frequently need surgery for a variety of medical issues, major procedures can also cause GBS. Certain drugs and long-term medical conditions can affect the immune system and perhaps aggravate GBS. The immune system changes with age, increasing the risk of GBS in the elderly population.

Restraining Factors

Inadequate awareness of the various treatments for Guillain-Barre syndrome (GBS) poses a serious obstacle to the market's expansion and has a detrimental effect on patient outcomes by delaying diagnosis and therapy.

Market Segmentation

The global Guillain-Barre syndrome market share is classified into type, treatment, route of administration, and distribution channel.

• The acute inflammatory demyelinating polyneuropathy segment dominated the market with 55.24% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the type, the global Guillain-Barre syndrome market is categorized into acute motor axonal neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, acute inflammatory demyelinating polyneuropathy, and Miller-Fisher syndrome. Among these, the acute inflammatory demyelinating polyneuropathy segment dominated the market with 55.24% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

The segmental growth is attributed to their influence on the peripheral nervous system, rapid muscle weakness, increasing recognition, and rising diagnosis of acute inflammatory demyelinating polyneuropathy.

• The intravenous immunoglobulin (IVIG) segment accounted for the largest market share of 48.15% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the treatment, the global Guillain-Barre syndrome market is categorized into plasma exchange, intravenous immunoglobulin (IVIG), and others. Among these, the intravenous immunoglobulin segment accounted for the largest market share of 48.15% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental growth is owing to mild side effects, highly sterilized, reduces the risk of infection, strengthens the immune system, reduces the inflammation, aids in the management of autoimmune conditions, and promotes the nerve healing. IVIG treatment neutralizes autoantibodies attacking peripheral nerves, improving recovery and reducing disease severity, driven by the high demand for plasma-derived immunoglobulins.

• The parenteral segment accounted for the largest market share of 58.41% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the route of administration, the global Guillain-Barre syndrome market is categorized into parenteral and oral. Among these, the parenteral segment accounted for the largest market share of 58.41% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to the enhanced bioavailability, targeted drug delivery, extensive usage by population, increasing demand of healthcare providers, reduces the gastric irritation, rapid onset of action, patient compliance and precise dosage.

• The hospital pharmacies segment held the largest market share of 50.33% in 2023 and is predicted to grow at a remarkable CAGR during the projected timeframe.

Based on the distribution channel, the global Guillain-Barre syndrome market is categorized into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment held the largest market share of 50.33% in 2023 and is predicted to grow at a remarkable CAGR during the projected timeframe. The segment's growth is accelerated by providing acute GBS treatments, such as IVIG therapy and plasmapheresis, due to their rapid progression and urgent need for immediate access to effective therapies, personalized treatment, access to specialized services, and facilities of the dispensing and compounding medications.

Regional Segment Analysis of the Global Guillain-Barre Syndrome Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe)
• Asia-Pacific (China, Japan, India, and the Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, and the Rest of MEA)

North America is anticipated to hold the largest share of the global Guillain-Barre syndrome market over the predicted timeframe.

North America is anticipated to hold the largest share of the global Guillain-Barre syndrome market over the predicted timeframe. The GBS market is experiencing rapid growth due to increased awareness, treatment options, and rising diagnosis rates. The U.S. and Canada are leading the way, with improved healthcare access and online pharmacy adoption enhancing accessibility. The U.S. is experiencing a higher incidence of GBS, with the CDC reporting a higher incidence. The demand for effective treatments, such as Intravenous Immunoglobulin (IVIG) and plasma exchange, is expected to rise, with therapies like IVIG and plasma exchange expected to see significant usage.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The GBS market in the Asia Pacific region is experiencing rapid growth, especially in countries like China, India, Japan, and Australia. The rise in GBS cases and the development of healthcare infrastructure are driving the growth of the market. The demand for therapies like IVIG and plasma exchange is increasing, particularly for managing severe forms like AIDP and AMAN. Japan's GBS market is also expanding due to lifestyle changes and increased awareness of GBS-related health risks. Hospital pharmacies play a crucial role in providing these treatments. China is experiencing significant growth in the GBS market due to increased awareness and demand for treatment options, particularly IVIG and plasma exchange for Miller Fisher Syndrome (MFS). Access to healthcare infrastructure, including hospital pharmacies, is driving the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Guillain-Barre syndrome market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• CSL Behring LLC
• Grifols SA
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Biogen Inc.
• F. Hoffmann-La Roche Ltd
• Merck and Co. Inc.
• Cadila Healthcare Limited
• LGM Pharmaceuticals Inc.
• Octapharma AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In December 2024, Annexon, Inc. announced positive results from a real-world evidence study supporting ANX005 as a potential treatment for Guillain-Barré Syndrome (GBS). ANX005, the most advanced targeted immunotherapy in development for GBS, is designed to block C1q and complement activity with a single dose to halt disease progression during the critical progressive phase of the disease. This advancement is part of Annexon's late-stage clinical platform of novel therapies for classical complement-mediated neuroinflammatory diseases.

• In December 2024, Hansa Biopharma reported positive results from a Phase 2 study on Imlifidase, a first-in-class IgG-cleaving enzyme, in Guillain-Barré Syndrome (GBS). The study also compared the data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a prospective study by the Inflammatory Neuropathy Consortium. The 15-HMedIdeS-09 study found that severe GBS patients treated with Imlifidase (0.25mg/kg) and IVIg experienced rapid functional improvement, including muscle strength recovery, fast return to independently walking, and a median time to independently walk by 16 days.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global Guillain-Barre syndrome market based on the below-mentioned segments:

Global Guillain-Bare Syndrome Market, By Type

• Acute Motor Axonal Neurotherapy
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• Acute Inflammatory Demyelinating Polyneuropathy
• Miller Fisher Syndrome

Global Guillain-Bare Syndrome Market, By Treatment

• Plasma Exchange
• Intravenous Immunoglobulin (IVIG)
• Others

Global Guillain-Bare Syndrome Market, By Route of Administration

• Parenteral
• Oral

Global Guillain-Bare Syndrome Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Guillain-Barre Syndrome Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa